Endologix is a global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease. Following a re-emergence as a private company, Endologix partnered with HDMZ to establish a new, distinctive brand that would earn the respect of key stakeholders and build confidence in an enduring vision to be a leading, global interventional vascular company. The resulting “Embrace the Evidence” campaign consisted of a comprehensive corporate identity campaign, messaging strategy and marcomm execution.
Endologix
Brand Transformation for the Transformation of Vascular Disease Treatment
About the project
Launching a Life-Saving Product
Shortly after the successful debut of the campaign, Endologix engaged HDMZ to launch a landmark addition to its portfolio: percutaneous transmural arterial bypass (PTAB) therapy using the DETOUR™ System. A breakthrough in the treatment of peripheral arterial disease (PAD), PTAB with the DETOUR System offers patients with PAD an alternative treatment option with comparable outcomes to surgical bypass while avoiding its complications.
